Vanguard reports 5.03% stake in Anavex Life Sciences
Vanguard Capital Management reports beneficial ownership of 4,663,459 shares of Anavex Life Sciences Corp common stock, representing 5.03% of the class as of June 30, 2026.
Rhea-AI Filing Summary
Vanguard Capital Management reports beneficial ownership of 4,663,459 shares of Anavex Life Sciences Corp common stock, representing 5.03% of the class as of June 30, 2026.
The firm has sole voting power over 608,870 shares and sole dispositive power over all 4,663,459 shares, with no shared voting or dispositive power. The position aggregates securities over which Vanguard Capital Management LLC and certain affiliates or business divisions exercise voting and/or dispositive power, including Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd. The holdings include Vanguard funds and other client accounts. Vanguard Capital Management and related investment companies and accounts have the right to receive or direct dividends and sale proceeds, but no other single person has an interest in more than 5% of this class through these holdings.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
beneficially owned financial
sole voting power financial
sole dispositive power financial
percent of class financial
Schedule 13G regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Which Vanguard entities are included in the AVXL Schedule 13G filing for Vanguard Capital Management?
Does any other person have more than a 5% interest in AVXL through Vanguard Capital Management’s holdings?
As of what date are Vanguard Capital Management’s AVXL holdings reported in this Schedule 13G?
AI-generated analysis. How Rhea-AI works. Not financial advice.